Abstract
In 2009, a cluster-randomized trial showed a 49% reduction in all-cause mortality among Ethiopian children 1 to 9 years of age in the year after mass distribution of a single dose of azithromycin for trachoma prevention — a reduction that was sustained over the following 26 months.1 This remarkable finding led to further multinational cluster-randomized trials examining mass distribution of azithromycin for children 1 to 59 months of age in trachoma-endemic areas of Niger, Tanzania, and Malawi (the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance [MORDOR] trial)2 and such distribution combined with seasonal malaria prophylaxis .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
